Compare Crispr Therapeutics AG (CRSP) vs Herbalife Nutrition Ltd (HLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Herbalife Nutrition Ltd — how do they compare? Crispr Therapeutics AG trades at $50.83 (market cap $4.97B), while Herbalife Nutrition Ltd trades at $12.39 (market cap $1.27B). The key difference: Crispr Therapeutics AG is far larger — about 3.9× Herbalife Nutrition Ltd's market cap, and Herbalife Nutrition Ltd is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | HLF | |
|---|---|---|
Market Cap | $4.97B | $1.27B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $19.96 |
52-Week Low | $44.34 | $7.75 |
Enterprise Value | $3.32B | $3.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Herbalife (HLF) trades at $13.10, down 0.38% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 77.78% gross margin and attractive valuation metrics including a P/E of 5.75 and P/S of 0.27. Recent Q1 2026 earnings beat expectations with EPS of $0.64 versus $0.607 expected, while the company completed a $1.45 billion debt refinancing in April 2026 to strengthen its balance sheet.
The outlook remains positive with analyst consensus favoring Buy ratings (57.69%) and improving debt-to-asset ratios from 82.84% in 2024 to 71.67% in 2025. Key risks include high leverage, competitive pressures in the nutrition space, and regional market volatility. The stock offers value appeal given low multiples and recent strategic initiatives to expand digital health offerings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Herbalife Nutrition Ltd
Herbalife Nutrition Ltd is an international nutrition company.
Read more on HLF →
